Journal articles: 'Thrombosis'

1

Sands, Jeffrey J., and Carol L. Miranda. "State-of-the-Art Review : Treatment of Hemodialysis Access Failure: A Role for Thrombolysis." Clinical and Applied Thrombosis/Hemostasis 2, no. 3 (July 1996): 164–68. http://dx.doi.org/10.1177/107602969600200304.

Full text

Abstract:

Thrombosis of hemodialysis accesses remains a major source of morbidity, hospitalization, and expense for patients with end-stage renal disease. Treatment of hemodialysis accesses includes strategies to prevent ac cess failure and methods for treating acute thromboses. Such techniques as Doppler ultrasonography, venous pressure monitoring during dialysis, measurement of ra tios of venous to systemic pressures, and measurement of recirculation have been used to predict accesses at risk of thrombosis. Elective interventions, including surgical re visions and angioplasties, have been shown to lessen the thrombosis rate in both polytetrafluoroethylene (PTFE) grafts and arterio-venous fistulas. Elective revision has also improved long-term patency of both grafts and fistu las when compared with repairing the accesses only after thrombosis. Despite these attempts, acute thrombosis of hemodialysis accesses remains a common complication for patients with end-stage renal disease. Historically, surgical thrombectomy has been the gold standard for treatment of acute hemodialysis access failure. Over the past 10 years, thrombolytic therapy has gained an in creasing role in the treatment of acutely thrombosed PTFE grafts. Thrombolysis has had at least comparable results to surgical thrombectomy in the best centers, with similar complication rates. Thrombolytic therapy is also significantly less expensive than surgical thrombectomy. In summary, we believe that hemodialysis access treat ment should encompass a comprehensive program, in cluding access surveillance to select accesses at risk of failure. Elective intervention should be performed in an attempt to prevent thrombosis and increase long-term ac cess patency. When thrombosis does occur, pharmaco mechanical thrombolysis is the preferable first interven tion for acutely occluded PTFE hemodialysis accesses.

APA, Harvard, Vancouver, ISO, and other styles

2

Kitchens, Craig S. "Thrombotic Storm: When Thrombosis Begets Thrombosis." American Journal of Medicine 104, no. 4 (April 1998): 381–85. http://dx.doi.org/10.1016/s0002-9343(98)00061-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mulcaire-Jones, John P., David K. Bailly, Deborah U. Frank, Anupam R. Verma, Bradley J. Barney, and Heather M. Siefkes. "Spontaneous aortic thrombosis in neonates: a case report and review of literature." Cardiology in the Young 30, no. 1 (January 2020): 95–99. http://dx.doi.org/10.1017/s1047951119003093.

Full text

Abstract:

AbstractNeonatal aortic thrombosis is a rare occurrence but can be life-threatening. Most aortic thrombosis in neonates is related to umbilical artery catheters. A case of a neonate with a spontaneous aortic thrombosis is described here along with a comprehensive review of the literature for cases of neonatal aortic thrombosis not related to any intravascular device or procedure. The aetiologies of these spontaneous thromboses and the relevance of hypercoagulable disorders are discussed. The cases were analysed for odds of death by treatment method adjusted for era. The reference treatment method was thrombolysis and anticoagulation. No other treatment modality had significantly lower odds than the reference. Surgery alone had higher odds for death than the reference, but this may be confounded by severity of case. The management recommendations for clinicians encountering neonates with spontaneous neonatal aortic thrombosis are discussed.

APA, Harvard, Vancouver, ISO, and other styles

4

Spaet, Theodore H. "Thrombosis and Thrombolysis." JAMA: The Journal of the American Medical Association 257, no. 19 (May 15, 1987): 2653. http://dx.doi.org/10.1001/jama.1987.03390190131040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hongsakul, Keerati, Sorracha Rookkapan, Jitpreedee Sungsiri, Ussanee Boonsrirat, and Boonprasit Kritpracha. "Pharmacomechanical Thrombolysis versus Surgical Thrombectomy for the Treatment of Thrombosed Haemodialysis Grafts." Annals of the Academy of Medicine, Singapore 44, no. 2 (February 15, 2015): 66–70. http://dx.doi.org/10.47102/annals-acadmedsg.v44n2p66.

Full text

Abstract:

Introduction: The key to treatment of a thrombosed dialysis graft is restoration and maintenance of function as long as possible. The objective of this study was to compare the outcomes of pharmacomechanical thrombolysis and surgical thrombectomy in the treatment of thrombosed haemodialysis grafts. Materials and Methods: During a 3-year period, 108 patients with 114 thrombosed dialysis grafts were referred to our institute for treatment. Fifty thrombosed dialysis grafts underwent pulse-spray catheter thrombolysis using recombinant tissue plasminogen activator (rt-PA) with angioplasty, and 64 thrombosed dialysis grafts underwent surgical thrombectomy. The procedural success rates, complications and average patency times and patency rates were compared between the 2 procedures. P values less than 0.05 were considered to be statistically significant. Results: There were no statistically significant differences between the pharmacomechanical thrombolysis group and the thrombectomy group in the procedural success rates (94% and 93.8%, P = 0.15) or average patency times (6.24 months and 6.30 months, P = 0.17). The primary and secondary patency rates at 12 months were 28.0% ± 8.4% and 54.3% ± 7.8% for the thrombolysis with angioplasty group, and 30.0% ± 6.3% and 57.0% ± 4.8% for the thrombectomy group, respectively (P = 0.65 and P = 0.49, respectively). There were no procedural-related major complications. Conclusion: Our study found no differences in outcomes between patients treated with pharmacomechanical thrombolysis and surgical thrombectomy for thrombosed haemodialysis grafts. Pharmacomechanical thrombolysis can be considered as an alternative treatment for dialysis graft thrombosis. Key words: Angioplasty, Arteriovenous graft, Thrombosis

APA, Harvard, Vancouver, ISO, and other styles

6

Fraschini, G., J. Jadeja, M. Lawson, F. A. Holmes, H. C. Carrasco, and S. Wallace. "Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients." Journal of Clinical Oncology 5, no. 4 (April 1987): 672–78. http://dx.doi.org/10.1200/jco.1987.5.4.672.

Full text

Abstract:

We assessed the efficacy of local fibrinolytic therapy in 35 axillary-subclavian vein thromboses (SVT) that occurred in cancer patients with percutaneous central venous catheters (CVC). These catheters were indwelling for a median of 1 month (range, one day to 10 months) before thrombosis developed. Urokinase was administered at a dose of 500 to 2,000 U/kg/h. Complete lysis occurred in 25 of 30 thrombi that were directly infused, after a median of four days. Complete lysis occurred in one of 12 thrombi that could not be directly infused with urokinase and in two of six with associated phlebitis. Eighty-one percent of the thrombi that were symptomatic for less than 1 week before treatment resolved, compared with 56% present for longer than 1 week. Sixteen patients who had complete (12) or partial (four) thrombolysis did not have their CVCs removed. All four patients with partial thrombolysis had recurrent thrombosis at a median of eight days (range, one to 90). Only two patients who had complete thrombolysis had recurrent thrombosis, at 8 and 16 months. Only minor hemorrhagic toxicity was seen.

APA, Harvard, Vancouver, ISO, and other styles

7

Cote, Julie, Olivier Dumas, Christine Demers, and Julie Lemieux. "Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e17517-e17517. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e17517.

Full text

Abstract:

e17517 Background: Tunnelled catheters (Leonard, BARD) and peripherally inserted central catheters (Piccline, BARD) are used for intravenous therapies in patients with malignancies. Thrombosis is a well known complication, but risk factors are not clearly established. The objective the incidence, risk factors, therapeutic approaches and complications of catheter-related thrombosis among patients with malignancies. Methods: Medical charts of patients with malignancies and Leonard or Piccline inserted, from August 2002 to December 2006 at Hôpital de l’Enfant-Jésus (Québec City, Canada), were retrospectively reviewed. Results: A total of 618 catheters were inserted in 361 patients. Eighty-six percent of the catheters were placed in patients with hematologic malignancies and most were Piccline (70%). Sixty-one thromboses were identified (incidence of 10%). Fourteen percent of the patients had more than one episode of catheter-related thrombosis. The majority of thromboses was related to a Piccline (93%) and occurred at a mean time of 34 days after the insertion. At the time of thrombosis, the mean platelet count was 169 x 109/L. Previous history of a catheter-related thrombosis (OR = 4.30 (1.48-12.50); p = 0.0075) as well as lymphoma (OR = 3.29 (1.22-8.87); p = 0.0185) were associated with superficial thromboses. The Piccline was associated with both types of thromboses (OR = 5.78 (1.69-19.74); p = 0.0051), especially with superficial thromboses. Most of the catheters (88%) were removed once a thrombosis was identified. The management of anticoagulation varied considerably. No complication associated with thromboses was reported. Conclusions: The incidence of central venous catheter-related thrombosis was 10%. The thrombosis occurred on average 34 days after the insertion. The Piccline was associated with all types of thromboses, especially the superficial ones. A previous history of catheter-related thrombosis and lymphoma were risk factors for superficial thromboses. Further studies are necessary to better define characteristics and optimal management of central catheter-related thrombosis.

APA, Harvard, Vancouver, ISO, and other styles

8

Mirza, Aram Jamal, and Abdulsalam Yaseen Taha. "Catheter directed thrombolysis for acute deep vein and arterial thrombosis in COVID-19: report of two cases from Sulaymaniyah, Kurdistan-Iraq." Journal of the Faculty of Medicine Baghdad 63, no. 2 (July 13, 2021): 74–79. http://dx.doi.org/10.32007/jfacmedbagdad.6321822.

Full text

Abstract:

Abstract As one year elapsed since COVID-19 outbreak, venous and arterial thromboses are increasingly reported in different vascular territories. Once accessed by the virus, the endothelial cells, abundant in angiotensin converting enzyme-2 (ACE-2) protein, will be activated by the inflammatory process leading to coagulopathy and vascular lesions. Herein, we describe a case of extensive thrombosis of the infra-renal inferior vena cava and iliac femoral vein in a man of 62 and a case of acute superficial femoral artery thrombosis in a lady of 55. Both were COVID-19 confirmed cases with severe pneumonia, high D-Dimer levels and risk factors for severe disease or death. Despite presentation 1-2 weeks after the onset of thromboses, they were successfully managed by catheter directed thrombolysis (CDT) using tissue plasminogen activator (tPA). Owing to the increased morbidity and mortality of vascular thrombosis, there is a need to identify COVID-19 patients who need prophylaxis and prescribe them the right prophylactic drug (s). The excellent outcome of CDT in these two patients, from Sulaymaniyah/Iraq, supports the use of this treatment modality as a valid, safe and effective option for acute arterial and venous thromboses.

APA, Harvard, Vancouver, ISO, and other styles

9

Koraen-Smith, Linn, Matteus Krasun, Matteo Bottai, Ulf Hedin, Carl M. Wahlgren, and Peter Gillgren. "Haemodialysis access thrombosis: Outcomes after surgical thrombectomy versus catheter-directed thrombolytic infusion." Journal of Vascular Access 19, no. 6 (April 3, 2018): 535–41. http://dx.doi.org/10.1177/1129729818761277.

Full text

Abstract:

Introduction: Thrombosis is one of the most common complications of dialysis vascular access and is a significant source of morbidity and healthcare-associated costs. In this retrospective study, outcomes for surgical thrombectomy and thrombolysis after access thrombosis in patients with arteriovenous fistulas or prosthetic grafts (arteriovenous grafts) were analysed. Methods: All patients with a primary episode of dialysis access thrombosis between 2005 and 2013 were included which yielded 131 patients with 149 episodes of access thrombosis (108 arteriovenous grafts; 41 arteriovenous fistulas). In all, 18 patients had two separate accesses during the study. Patient demographics, access anatomy, surgical and radiological procedural data were recorded. Kaplan–Meier estimates and Poisson regression were used for statistical analysis of access patency. Results: In total, 107 underwent surgical thrombectomy and 42 were treated with catheter-directed thrombolytic infusion. Technical success was 60% for surgical thrombectomy and 73% for thrombolysis (p = 0.18). There were no major complications and no deaths within 30 days of the procedure. More patients had adjunctive procedures in the thrombolysis group (65/107 vs 37/42; p = 0.002). There was an increasing risk of rethrombosis or a further access-related event for both arteriovenous fistulas and arteriovenous grafts after open thrombectomy compared with catheter-directed thrombolytic infusion, and arteriovenous fistulas exhibited a lower risk than arteriovenous grafts with an average increase in risk of 23.9% (95% confidence interval: 3.1–49) between each treatment group. Conclusion: Thrombolysis for thrombosis of native and prosthetic dialysis accesses appears to yield better assisted primary patency compared to surgical thrombectomy. Our results suggest that thrombolysis may be considered the first-choice method for treating the thrombosed dialysis access.

APA, Harvard, Vancouver, ISO, and other styles

10

Kröger, K., C. Schelo, C. Gocke, and G. Rudofsky. "Colour Doppler Sonographic Diagnosis of Upper Limb Venous Thromboses." Clinical Science 94, no. 6 (June 1, 1998): 657–61. http://dx.doi.org/10.1042/cs0940657.

Full text

Abstract:

1. Upper limb venous thromboses are considered to be a rare event, but in large hospitals with a lot of patients who receive aggressive intravenous therapy the number of thromboses seem to increase. 2. We have analysed all the cases of upper limb venous thrombosis which occurred at the Essen University Hospital between the years of 1992–1996. All patients were examined using colour Doppler sonography. 3. Out of 827 patients that were examined, a thrombosis was diagnosed in 334 cases. The subclavian vein was involved in 69% of all thromboses. Isolated jugular vein thrombosis was found in 17% of the thromboses, combined thromboses of the jugular and subclavian vein in 19%. In 182 cases the patients were treated for primarily a malignant illness. In 96 cases we found an association with venous port-systems or central venous catheters. 4. More than 40000 patients a year were treated at the university hospital. Considering this huge number of patients the thrombosis of the upper limb is still rare. The use of colour Doppler sonography allows an early and safe diagnosis of the thrombosis without straining the patient.

APA, Harvard, Vancouver, ISO, and other styles

11

Stefano, Valerio De, and Ida Martinelli. "Rare thromboses of cerebral, splanchnic and upper-extremity veins." Thrombosis and Haemostasis 103, no. 06 (2010): 1136–44. http://dx.doi.org/10.1160/th09-12-0873.

Full text

Abstract:

SummaryVenous thrombosis typically involves the lower extremity circulation. Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate. A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome. The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses. Local risk factors such as infections or cancer are frequent in thrombosis of cerebral or portal veins. Upper extremity deep-vein thrombosis is mostly due to local risk factors (catheter- or effort-related). Common systemic risk factors for rare venous thromboses are inherited thrombophilia and oral contraceptive use; chronic myeloproliferative neoplasms are closely associated with splanchnic vein thrombosis. In the acute phase rare venous thromboses should be treated conventionally with low-molecular-weight heparin. Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation. Anticoagulation with vitamin K-antagonists is recommended for 3–6 months after a first episode of rare venous thrombosis. Indefinite anticoagulation is recommended for Budd-Chiari syndrome, recurrent thrombosis or unprovoked thrombosis and permanent risk factors. In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms. However, the recommendations for treatment mainly derive from observational studies.

APA, Harvard, Vancouver, ISO, and other styles

12

Levrier, O., J. M. Stordeur, N. Bruder, L. Manera, P. Bouillot, and C. H. Raybaud. "Postoperative Intracranial Thrombolysis and Angioplasty." Interventional Neuroradiology 7, no. 4 (December 2001): 325–30. http://dx.doi.org/10.1177/159101990100700408.

Full text

Abstract:

The case study involves a patient presenting middle cerebral artery thrombosis, related to a severe vasospasm following subarachnoid hemorrhage due to aneurysm rupture. The patient was treated initially by surgical clipping of the left middle cerebral artery aneurysm. After surgery, the neurological status of the patient was normal. Six days later, the patient presented right hemiplegia and aphasia that were related to the proximal left middle cerebral artery thrombosis. Despite recent open-skull surgery, in situ thrombolysis using urokinase and antiplatelet antibodies (abciximab) was performed. The thrombosed artery was reopened and a severe vasospasm was observed. The vasospasm was treated by transluminal angioplasty. No intracranial hemorrhage was noted after thrombolysis and angioplasty, whereas subcutaneous hemorrhage around the scalp incision was observed. The patient recovered from motor and language impairment. The only long-term symptom was a mild dysorthographia. Balance of risk/benefit is discussed for such aggressive thrombolytic therapy. In this particular case, effectiveness and uneventful use of abciximab was demonstrated despite very recent brain surgery that was considered a formal contra-indication for the use of such a powerful thrombolytic drug. Vessel thrombosis is an exceptional complication of cerebral vasospasm. In the early hours, intra-arterial thrombolysis may be considered, but recent intracranial surgery is usually an exclusion criterion to performing thrombolysis. We report the case of a patient who underwent thrombolysis and angioplasty in the postoperative period to treat this complication of vasospasm.

APA, Harvard, Vancouver, ISO, and other styles

13

Bregel, L. V., O. S. Efremova, M. M. Kostik, N. Yu Rudenko, T. S. Korinets, N. S. Drantusova, A. O. Barakin, et al. "MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN ASSOCIATED WITH COVID-19 AND COMPLICATED BY VENOUS AND ARTERIAL THROMBOSES: A SERIES OF CLINICAL CASES." Pediatria. Journal named after G.N. Speransky 103, no. 3 (June 14, 2024): 56–70. http://dx.doi.org/10.24110/0031-403x-2024-103-3-56-70.

Full text

Abstract:

SARS-CoV-2 causative agent may result in adulthood in hyperinflammatory syndrome and cytokine storm in some patients leading to the microvascular bed thromboses as well as those of large venous and arterial vessels. In the COVID-19 critical form, multisystem inflammatory syndrome in children (MIS-C), thromboses are less common. Authors represent a series of 8 patients’ cases with both thromboses and MIS-C associated with COVID-19 of different localization hospitalized in Nov. 2020-Nov. 2022 aged 4 months to 17 years old (Me 7.5 y/o): 4 aged 4 m/o to 5 y/o and 4 aged 8 to 17 y/o; 6 boys/2 girls. The incidence of thromboses was 13.3% (8/60 pediatric patients with MIS-C); venous thrombosis occurred in 6 (10% of 60), arterial thrombosis in 4 (6.6%), large cerebral vessels thrombosis coupled with the development of bilateral stroke occurred in 2 (3.3%), secondary thrombotic microangiopathy (TMA) in 3 (5%), distal gangrene in a single case (1.7%) and the cerebral venous sinus thrombosis in a single case (1.7%) as well. Treatment was carried out with anticoagulants, aspirin, immunomodulators (intravenous immunoglobulin, glucocorticosteroids, genetically engineered biological drugs). One of 8 patients with thromboses had died from pulmonary embolism (1.7% among all 60 patients with MIS-C), 6 of the 7 survivors continue to be followed up without complications and a single patient continues to have residual severe neurological deficits. Conclusion: venous thrombosis, secondary TMA and large cerebral arteries thrombosis predominated. Treatment of thrombosis with unfractionated heparin intravenously by continuous infusion with a transition to low molecular weight heparins against the background of pathogenetic therapy for MIS-C with immunomodulators was effective in most patients. Acetylsalicylic acid was used in 3 (with coronary dilatation and/or absence of severe thrombocytopenia). Risk factors for thromboses were male gender, severe congenital underlying diseases.

APA, Harvard, Vancouver, ISO, and other styles

14

Stake, Seth, Anne L. du Breuil, and Jeremy Close. "Upper Extremity Deep Vein Thromboses: The Bowler and the Barista." Case Reports in Vascular Medicine 2016 (2016): 1–4. http://dx.doi.org/10.1155/2016/9631432.

Full text

Abstract:

Effort thrombosis of the upper extremity refers to a deep venous thrombosis of the upper extremity resulting from repetitive activity of the upper limb. Most cases of effort thrombosis occur in young elite athletes with strenuous upper extremity activity. This article reports two cases who both developed upper extremity deep vein thromboses, the first being a 67-year-old bowler and the second a 25-year-old barista, and illustrates that effort thrombosis should be included in the differential diagnosis in any patient with symptoms concerning DVT associated with repetitive activity. A literature review explores the recommended therapies for upper extremity deep vein thromboses.

APA, Harvard, Vancouver, ISO, and other styles

15

Matsuyama, Nanritsu, Kunio Asada, Keiichiro Kondo, Toshihiro Kodama, Seiichiro Minohara, Shigeto Hasegawa, Yoshihide Sawada, et al. "Thrombolysis for Bileaflet Valve Thrombosis." Japanese Journal of Cardiovascular Surgery 28, no. 1 (1999): 39–43. http://dx.doi.org/10.4326/jjcvs.28.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Cesarone, Maria R., Glanni Belcaro, Maria Teresa De Sanclis, Marco Bucci, Andrea Di Renzo, Lucrezia Incandela, Ernst Marlinghaus, and Andrew Nicolaides. "Arterial thrombosis: shock wave thrombolysis." Journal of the American College of Cardiology 39 (March 2002): 7. http://dx.doi.org/10.1016/s0735-1097(02)80025-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Berridge, D. C., A. Al-Kutoubi, A. O. Mansfield, A. N. Nicolaides, and J. H. N. Wolfe. "Thrombolysis in arterial graft thrombosis." European Journal of Vascular and Endovascular Surgery 9, no. 2 (February 1995): 129–32. http://dx.doi.org/10.1016/s1078-5884(05)80080-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Rana, K. G. S., A. Jhamb, Mukul Verma, and Harsh Rastogi. "Thrombolysis for Cerebral Venous Thrombosis." Apollo Medicine 4, no. 1 (March 2007): 69–71. http://dx.doi.org/10.1016/s0976-0016(11)60439-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Gupta, A. K., T. R. Kapilamoorthy, T. Bejoy, J. Santhosh, and C. Kesavadas. "Thrombolysis in Dural Sinus Thrombosis." Rivista di Neuroradiologia 16, no. 6 (December 2003): 1339–41. http://dx.doi.org/10.1177/197140090301600686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Comerota, Anthony J. "Thrombolysis for deep venous thrombosis." Journal of Vascular Surgery 55, no. 2 (February 2012): 607–11. http://dx.doi.org/10.1016/j.jvs.2011.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Renowden, Shelley. "Cerebral venous thrombosis: Local thrombolysis." Journal of the Royal Society of Medicine 93, no. 5 (May 2000): 241–43. http://dx.doi.org/10.1177/014107680009300507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Demey, Hendrik E., Guy Lambrecht, Greta Moorkens, Peter Michielsen, Jef Van Den Ende, and Leo L. Bossaert. "Thrombolysis in Central Splanchnic Thrombosis." Journal of Intensive Care Medicine 12, no. 5 (September 1997): 269–75. http://dx.doi.org/10.1177/088506669701200508.

Full text

Abstract:

We present 4 patients treated with streptokinase for different forms of abdominal venous thrombosis. Two patients suffered from central splanchnic venous thrombosis (superior mesenteric vein and bilateral iliac veins in Patient A, portal and superior mesenteric veins in Patient B). Both patients' presenting complaint was abdominal pain. In both, a temporary infection-associated circulating lupus anticoagulant presumably caused this condition. Two other patients presented with isolated portal vein thrombosis without lupus anticoagulant. Thrombolysis with high dose streptokinase (9 MU over 6 hours) successfully reopened the veins involved in all 4 patients. A literature survey showed that thrombolysis is a therapeutic option for mesenteric vein thrombosis, but there was no consensus on which thrombolytic drug should be given or on method of administration.

APA, Harvard, Vancouver, ISO, and other styles

23

Pilger, E., M. Decrinis, A. Obernosterer, and G. Stark. "Thrombolysis in deep venous thrombosis." Vascular Medicine Review vmr-1, no. 2 (September 1990): 167–78. http://dx.doi.org/10.1177/1358836x9000100206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Vitale, Nicola, Luigi de Luca, Attilio Renzulli, and Maurizio Cotrufo. "Thrombolysis for prosthetic valve thrombosis." Annals of Thoracic Surgery 59, no. 4 (April 1995): 1045. http://dx.doi.org/10.1016/0003-4975(95)95742-q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rassin, Tovi, Walter Desmet, Jan Piessens, and Uri Rosenschein. "Ultrasound thrombolysis in stent thrombosis." Catheterization and Cardiovascular Interventions 51, no. 3 (2000): 332–34. http://dx.doi.org/10.1002/1522-726x(200011)51:3<332::aid-ccd22>3.0.co;2-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Snyder, Kathryn D., Lamiya T. Rodriguez, and Colin Barker. "THROMBOLYSIS IN LATE TAVR THROMBOSIS." Journal of the American College of Cardiology 83, no. 13 (April 2024): 3775. http://dx.doi.org/10.1016/s0735-1097(24)05765-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rana, K. G. S., A. Jhamb, Mukul Verma, and Harsh Rastogi. "Thrombolysis for Cerebral Venous Thrombosis." Apollo Medicine 4, no. 1 (March 2007): 69–71. http://dx.doi.org/10.1177/0976001620070114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

ASAKURA, HIDESAKU. "Thrombosis. Thrombosis : Advances on diagnosis and treatment. Disease state and diagnosis of thrombotic diseases. Acquired thrombotic tendency. Hyperlipidemia and thrombosis." Nihon Naika Gakkai Zasshi 86, no. 6 (1997): 953–58. http://dx.doi.org/10.2169/naika.86.953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Elezovic, Ivo. "Role of gene polymorphism in development of thromboses." Srpski arhiv za celokupno lekarstvo 134, Suppl. 1 (2006): 64–71. http://dx.doi.org/10.2298/sarh06s1064e.

Full text

Abstract:

The development of thromboses is one of the most common causes of morbidity and mortality in the Western world. The perturbation of haemostasis is the central event in the pathogenesis of all thromboses. Most patients with thromboses have no recognisable associated haemostatic disorders. However, some patients do manifest hereditary hypercoagulable states, which contribute to the development of thromboses as well as other clinical manifestations, such as miscarriages and foetal complications. The major determinants of thrombosis include both environmental influences and genetic factors. Transient or long-lasting environmental influences may play important roles in arterial and venous thromboses. Haemostatic perturbance may also be genetically determined and exert a life-long influence. Specific mutations of genes predisposed to thrombosis, such as deficiency of antithrombin, protein C, or protein S, are found in relatively small number of families. In the absence of genetic deficiencies, thrombosis occurs in the older population, largely within the context of marked environmental influences (such as surgery, obesity, and malignancy). In contrast, familial thrombosis, associated with gene mutation, is associated with a younger age. The general importance of gene polymorphism was established after the recognition of activated protein C resistance (APCR) due to gene polymorphism G1691A in factor V (Factor V Leiden). This single gene defect increases the risk of venous thrombosis, without interaction with other genetic or environmental risk factors. The development of APCR led to many other investigations of gene polymorphism, such as prothrombin 20210, thrombomodulin, factors in the coagulation and fibrinolytic system, glycoproteins of platelet membranes, as well as polymorphism C677T of methylene tetrahydrofolate reductase. The number of potential genetic risk factors for occlusive thrombotic disease has increased significantly. Most of these gene polymorphisms increase the risk of venous thrombosis but there is no strong evidence of their influence as far as arterial thrombosis is concerned.

APA, Harvard, Vancouver, ISO, and other styles

30

Karaarslan, Ahmet A., Ahmet Karakaşlı, Aslan Mayda, Tolga Karcı, Hakan Aycan, and Şenol Kobak. "Traumatic Distal Ulnar Artery Thrombosis." Case Reports in Orthopedics 2014 (2014): 1–2. http://dx.doi.org/10.1155/2014/983160.

Full text

Abstract:

This paper is about a posttraumatic distal ulnar artery thrombosis case that has occurred after a single blunt trauma. The ulnar artery thrombosis because of chronic trauma is a frequent condition (hypothenar hammer syndrome) but an ulnar artery thrombosis because of a single direct blunt trauma is rare. Our patient who has been affected by a single blunt trauma to his hand and developed ulnar artery thrombosis has been treated by resection of the thrombosed ulnar artery segment. This report shows that a single blunt trauma can cause distal ulnar artery thrombosis in the hand and it can be treated merely by thrombosed segment resection in suitable cases.

APA, Harvard, Vancouver, ISO, and other styles

31

Taha, Mohamed AH, Andrew Busuttil, Roshan Bootun, and Alun H. Davies. "A systematic review of paediatric deep venous thrombolysis." Phlebology: The Journal of Venous Disease 34, no. 3 (June 3, 2018): 179–90. http://dx.doi.org/10.1177/0268355518778660.

Full text

Abstract:

Objectives The aim was to assess the effectiveness and safety of catheter-directed thrombolysis in children with deep venous thrombosis and to evaluate its long-term effect. Method and results EMBASE, Medline and Cochrane databases were searched to identify studies in which paediatric acute deep venous thrombosis patients received thrombolysis. Following title and abstract screening, seven cohort studies with a total of 183 patients were identified. Technical success was 82% and superior in regional rather than systemic thrombolysis (p < 0.00001). One cohort study identified significant difference in thrombus resolution at one year between thrombolytic and anticoagulant groups (p = 0.01). The complication rate was low, with incidence rates of major bleeding, pulmonary embolism and others at 2.8%, 1.8% and 8.4%, respectively. The overall post-thrombotic syndrome rate was 12.7%. The incidence of re-thrombosis ranged from 12.3% to 27%. Conclusion Thrombolysis for paediatric deep venous thrombosis is an effective and relatively safe therapeutic option, lowering the incidence of post-thrombotic syndrome and deep venous thrombosis recurrence.

APA, Harvard, Vancouver, ISO, and other styles

32

Bick, Rodger L. "Sticky Platelet Syndrome: A Common Cause of Unexplained Arterial and Venous Thrombosis." Clinical and Applied Thrombosis/Hemostasis 4, no. 2 (April 1998): 77–81. http://dx.doi.org/10.1177/107602969800400201.

Full text

Abstract:

Sticky platelet syndrome (SPS) was first described in 1983. However, not until 1995 did the prevalence of SPS receive significant recognition in the medical literature. In 1995 we began to routinely add an SPS evaluation to patients re ferred for assessment for causation of arterial and venous thromboses to a large thrombosis hemostasis referral center. The results of our first 2-year experience suggest SPS to be a common cause of arterial and venous thromboses. With respect to otherwise unexplained venous thrombosis, the prevalence of SPS approximates that of activated protein C resistance (APC- R). During the past 24 months, we have evaluated 153 patients referred for evaluation of unexplained arterial or venous events. An evaluation for common and uncommon blood coagulation protein defects and SPS has been applied to these patients. It has been found that SPS accounted for about 21 % of otherwise unexplained arterial events (acute myocardial infarction, cere brovascular thrombosis, transient cerebral ischemic attacks, retinal thrombosis, and peripheral arterial thrombosis) and ac counted for about 13.2% of otherwise unexplained venous events (deep vein thrombosis, with or without pulmonary em bolus). These findings strongly suggest SPS to be a common cause of arterial and venous thromboses and a workup for SPS should be considered a routine assay in the workup of indi viduals with otherwise unexplained arterial or venous throm botic events. Because treatment with heparin or warfarin will not alleviate the thrombotic tendency of SPS, but simple aspirin therapy almost always will correct the defect and protect the individual from second events, it is particularly important to define the presence of this defect. Key Words: Thrombosis— Platelet defects—DVT—Coronary thrombosis—Cerebral thrombosis—Recurrent miscarriage.

APA, Harvard, Vancouver, ISO, and other styles

33

Kander, Elizabeth, Qiuhong Zhao, Tracy Wiczer, John C. Byrd, Jennifer A. Woyach, Farrukh T. Awan, Kerry A. Rogers, and Tzu-Fei Wang. "Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment." Blood 132, Supplement 1 (November 29, 2018): 3148. http://dx.doi.org/10.1182/blood-2018-99-110556.

Full text

Abstract:

Abstract BACKGROUND: Ibrutinib is an irreversible inhibitor of BTK in the B-cell receptor signaling cascade and is widely used to treat chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Ibrutinib also inhibits the tyrosine kinase Tec in platelets, which may be one of the mechanisms of its bleeding toxicity. This makes concomitant use of anticoagulation (AC) or antiplatelet agents challenging, which is a common delimma as many patients taking ibrutinib are elderly and have increased risks of venous and arterial thromboses. The incidence of thrombosis in patients taking ibrutinib is unknown, and we hypothesized that the risk of thrombosis may be reduced during ibrutinib treatment. Therefore, we conducted a single-institution retrospective cohort study to determine the incidence and type of both arterial and venous thromboses during ibrutinib treatment and their management. METHODS: We reviewed medical records of all patients treated with ibrutinib for a hematological malignancy at the Ohio State University between 6/1/2010 and 3/31/2016. Baseline patient and disease characteristics were captured at time of starting ibrutinib. All thrombotic events occurring at any time during treatment with ibrutinib and within three days of its discontinuation were recorded. Time to thrombosis was calculated from the date of starting ibrutinib to the date of thrombosis or censored at the last assessment date, treating discontinuation of ibrutinib or death prior to thrombosis as competing risks. The cumulative incidence of thrombosis was estimated and the Fine and Gray regression models accounting for competing riskes were used to examine the association between patient characteristics and risk of thrombosis. RESULTS: The cohort included 565 patients. Median age was 65 (range 23->89) years and 70.3% (397/565) were men. The majority of patients had CLL (73.6%, 416/565). Other diagnoses included mantle cell lymphoma (9.9%, 56/565), indolent B-cell malignancies (8.1%, 46/565), and aggressive lymphomas (8.3%, 47/565). Median number of prior treatments was 3 (range 0-18) and 6.5% (37/565) of patients were treatment naïve. Prior to ibrutinib, 144 of 565 patients (25.5%) had a history of thrombosis. Sixty-four (11.3%, 64/565) patients had only venous thromboses, 66 (11.7% 66/565) had only arterial thromboses, and 14 patients had both. Concurrently with ibrutinib, 193 (34.2%) patients received antiplatelet agents, 16 (2.8%) patients received AC, and 31 (5.5%) patients received both. Total ibrutinib exposure for the cohort was 1,429 person-years with a median exposure of 2.39 (range 0-7.36) years per patient. A second antineoplastic agent was given with ibrutinib in 30.8% (174/565) of cases, including an immunomodulatory drug in 24 (4.2%, 24/565) patients. During ibrutinib treatment, 22 of 565 (3.9%) patients experienced 24 acute thrombotic events, mostly arterial (Table 1). The incidence of thrombosis was 1.7 (95% CI 1.1-2.5) per 100 person-years of ibrutinib exposure. Of the venous thromboses, 87.5% (7/8) were deep vein thromboses and developed at a median of 7.5 (range 0.5-75.3) months after starting ibrutinib. Of the arterial thromboses, the majority were acute cerebrovascular accidents (37.5%, 6/16) and developed at a median of 27.4 (range 0.4 - 56.6) months after starting ibrutinib. Thrombosis treatment is summarized in Table 1. After thrombosis, ibrutinib was discontinued or held in the majority of cases (75%, 18/24). One patient developed a recurrent thrombosis while on ibrutinib and AC. There were six bleeding events, 3 major (based on ISTH criteria) and 3 minor: all were taking ibrutinib and most were on AC (2 patients on antiplatelet, 1 on AC, 2 on both, 1 on neither). On univariable analysis, the only factors associated with significant (p<0.05) and substantial (HR >2) increased risk of venous thrombosis were prior venous (HR 4.73, CI: 1.06-21.11) and arterial (HR 15.66, CI: 3.07-79.87) thromboses. Antiplatelet use was not significantly associated with either thrombus type. CONCLUSIONS: The cumulative incidence of thrombosis during ibrutinib treatment was low (1.7 per 100 person-years), with the majority being arterial. Prior thrombosis was associated with increased venous thrombosis risk. There are more bleeding than thrombotic complications after patients develop thromboses on ibrutinib, and optimal treatment strategies for this population requires further investigation. Disclosures Kander: AstraZeneca: Consultancy. Wang:Daiichi Sankyo: Consultancy, Other: Travel.

APA, Harvard, Vancouver, ISO, and other styles

34

Smalberg, Jasper H., Manon V. M. C. W. Spaander, Kon-Siong G. Jie, Peter M. T. Pattynama, Henk R. van Buuren, Bart van den Berg, Harry L. A. Janssen, and Frank W. G. Leebeek. "Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis." Thrombosis and Haemostasis 100, no. 12 (2008): 1084–88. http://dx.doi.org/10.1160/th08-01-0015.

Full text

Abstract:

SummaryTranscatheter local thrombolytic therapy in patients with acute, extended splanchnic venous thrombosis is controversial. Here we present our single-center experience with transcatheter thrombolytic therapy in these patients. All consecutive patients (n=12) with acute,extended splanchnic venous thrombosis who underwent transcatheter thrombolytic therapy in our hospital, were included in this study. Thrombolytic therapy was successful for three thrombotic events and partially successful for four thrombotic events.Two patients developed minor procedure-related bleeding (17%).Six patients (50%) developed major procedure-related bleeding, with a fatal outcome in two. Transcatheter thrombolytic therapy in patients with acute, extended splanchnic vein thrombosis is found to be associated with a high rate of procedure-related bleeding. Therefore, thrombolysis should be reserved for patients in whom the venous flow cannot be restored by using conventional anticoagulant therapy or stent placement across the thrombosed vessel segment.H.L.A. Janssen and F.W.G. Leebeek are both Clinical Fellows of the Netherlands Organisation for Scientific Research (NWO).

APA, Harvard, Vancouver, ISO, and other styles

35

ROMERO-DÍAZ, JUANITA, ICELLINI GARCÍA-SOSA, and JORGE SÁNCHEZ-GUERRERO. "Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent Onset." Journal of Rheumatology 36, no. 1 (January 2009): 68–75. http://dx.doi.org/10.3899/jrheum.071244.

Full text

Abstract:

ObjectiveTo determine the risk of thrombosis in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases of recent onset.MethodsA retrospective cohort of 482 patients, mean age 28.3 years, with SLE or other autoimmune diseases was analyzed. Followup started at diagnosis or first appointment within 12 months since diagnosis until the development of thrombosis, end of study, loss to followup, or death. Thromboses were diagnosed upon clinical manifestations and confirmed by appropriate studies. Clinical variables were retrieved from the medical records, and SLE activity was assessed from the medical notes at onset of thrombosis, or at a dummy date for thrombosis, using the SLE Disease Activity Index-2K.ResultsDuring 2936 patient-years of followup, thromboses occurred in 49 patients (20.3%) with SLE and 6 patients (2.5%) with other autoimmune diseases. The incidence rate of thrombosis was 36.3 and 3.8 per 1000 patient-years in SLE and in other autoimmune diseases, respectively; relative risk 9.6 (95% CI 4.1–27.4, p < 0.0001). Throughout the disease course, the risk of thrombosis remained high in the SLE group, while in patients with other autoimmune diseases this risk was lower. The incidence of venous and arterial thrombosis was similar among SLE patients and patients with other autoimmune diseases. SLE and venous insufficiency were associated with thromboses in the total study population, and with venous insufficiency, vasculitis, and disease activity in the SLE group.ConclusionPatients with autoimmune diseases, particularly SLE, are at an increased risk of thrombosis. In patients with SLE, the risk remains elevated throughout the course of the disease.

APA, Harvard, Vancouver, ISO, and other styles

36

Heidrich, Konau, and Hesse. "Asymptomatic venous thrombosis in cancer patients – a problem often overlooked. Results of a retrospective and prospective study." Vasa 38, no. 2 (May 1, 2009): 160–66. http://dx.doi.org/10.1024/0301-1526.38.2.160.

Full text

Abstract:

Background: Venous thrombosis with and without pulmonary embolism is a frequent complication of malignancies and second among the causes of death in tumour patients. Its incidence is reported to be 10 to 15%. Since for methodological reasons, this rate can be assumed to be too low and to disregard asymptomatic venous thrombosis, a combined retrospective and prospective study was performed to examine the actual frequency of venous thrombosis in tumour patients. Patients and methods: The histories of 409 patients (175 women, 234 men, mean age 69 years [19 to 96 years]) with different tumours, consecutively enrolled in the order of their altogether 426 inpatient treatments, were checked in retrospect for the frequency of venous thrombosis and pulmonary embolism. Subsequently, 97 tumour inpatients (36 women, 61 men, mean age 70 years [42 to 90 years]) were systematically screened, by means of duplex sonography and/or venography, for venous thromboses in the veins of the pelvis and both legs. Results: In the retrospective analysis, where no systematic screening for thromboses was performed and only symptomatic thrombosis was recorded, venous thrombosis was found in 6.6% of all tumour patients, whereas in the prospective examination with systematic duplex sonography and / or venography of all patients, the percentage was 33%. In the prospective study, 31.3% of venous thromboses were symptomatic and 68.7% asymptomatic. In 39.3% of the cases in the retrospective analysis and 25% in the prospective analysis, venous thrombosis occurred during chemotherapy, surgery or radiation therapy. Venous thrombosis was most often seen in metastasizing tumours and in colorectal carcinoma (40%), haematological system diseases (28.6%), gastric cancer (30%), bronchial, pancreas and ovarian carcinoma (28.6%), and carcinoma of the prostate (16.7%). Conclusion: Regular screening for thrombosis is indicated even in asymptomatic tumour patients because asymptomatic venous thrombosis is frequent, can lead to pulmonary embolism and has to be treated like symptomatic venous thrombosis. This is particularly true for metastasization during chemotherapy, surgical interventions, or radiation.

APA, Harvard, Vancouver, ISO, and other styles

37

Hall, Claire, Stephen Richards, and Peter Hillmen. "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)." Blood 102, no. 10 (November 15, 2003): 3587–91. http://dx.doi.org/10.1182/blood-2003-01-0009.

Full text

Abstract:

AbstractParoxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia in which venous thrombosis is the most common cause of death. Here we address the risk factors for thrombosis and the role of warfarin prophylaxis in PNH. The median follow-up of 163 PNH patients was 6 years (range, 0.2-38 years). Of the patients, 29 suffered thromboses, with a 10-year incidence of 23%. There were 9 patients who presented with thrombosis, and in the remainder the median time to thrombosis was 4.75 years (range, 3 months-15 years). The 10-year risk of thrombosis in patients with large PNH clones (PNH granulocytes > 50%) was 44% compared with 5.8% with small clones (P < .01). Patients with large PNH clones and no contraindication to anticoagulation were offered warfarin. There were no thromboses in the 39 patients who received primary prophylaxis. In comparison, 56 patients with large clones and not taking warfarin had a 10-year thrombosis rate of 36.5% (P = .01). There were 2 serious hemorrhages in more than 100 patient-years of warfarin therapy. Large PNH granulocyte clones are predictive of venous thrombosis, although the exact cut-off for clone size is still to be determined. Primary prophylaxis with warfarin in PNH prevents thrombosis with acceptable risks. (Blood. 2003;102:3587-3591)

APA, Harvard, Vancouver, ISO, and other styles

38

Konings, Renske, Rutger J. Lely, Shaikh A. Nurmohamed, and Arjan W. J. Hoksbergen. "Successful Reversal of Acute Kidney Failure by Ultrasound-Accelerated Thrombolysis of an Occluded Renal Artery." Case Reports in Medicine 2014 (2014): 1–4. http://dx.doi.org/10.1155/2014/205646.

Full text

Abstract:

Purpose. To describe the treatment of renal artery thrombosis with ultrasound-accelerated thrombolysis and discuss the management of prolonged renal ischemia.Case. A 76-year-old patient with a single functional kidney, mild chronic renal impairment, and a recent history of endovascular repair of a thoracoabdominal aneurysm with an aortic branch graft presented with acute flank pain, anuria, and renal failure. The side branch from the aortic stent graft to his single, right, functional kidney appeared to be completely thrombosed. Symptoms had started after cessation of oral anticoagulants because of a planned mastectomy for breast cancer. After identification of the occlusion, ultrasound-accelerated thrombolysis was started 19 hours after the onset of anuria. Angiography, 4 hours after beginning of therapy, already showed partial dissolution of the thrombus and angiographic control after 18 hours showed complete patency of the renal artery side branch. Despite a long period of ischemia, renal function was completely recovered.Conclusion. In patients with acute renal ischemia due to thrombosis of the renal artery, complete recovery of function can be achieved with ultrasound-accelerated thrombolysis, even after prolonged periods of ischemia.

APA, Harvard, Vancouver, ISO, and other styles

39

Zhang, Dyan Zhewei, Teng Hong Tan, Kenneth Pak Leung Wong, Sreekanthan Sundaraghavan, and Jonathan Tze Liang Choo. "Reperfusion Injury with Compartment Syndrome Following Systemic Thrombolysis for Cardiac Catheterization-Related Arterial Thrombosis in an Infant." Journal of Pediatric Intensive Care 09, no. 01 (November 1, 2019): 074–76. http://dx.doi.org/10.1055/s-0039-1700522.

Full text

Abstract:

AbstractSystemic thrombolysis is increasingly used for management of arterial thrombosis following cardiac catheterization, and complications apart from bleeding manifestations are not well reported. We report the case of an infant with lower limb ischemia secondary to femoral arterial thrombosis, which developed after cardiac catheterization. Systemic thrombolysis resulted in successful reperfusion of the lower limb. However, the infant subsequently developed compartment syndrome, requiring an emergent fasciotomy. This case highlights the importance of surveillance for the development of reperfusion injury-related compartment syndrome postsystemic thrombolysis for arterial thrombosis.

APA, Harvard, Vancouver, ISO, and other styles

40

KAIZU, KAZO. "Thrombosis. Thrombosis : Advances on diagnosis and treatment. Disease state and diagnosis of thrombotic diseases. Acquired thrombotic tendency. Diabetes mellitus and thrombosis." Nihon Naika Gakkai Zasshi 86, no. 6 (1997): 947–52. http://dx.doi.org/10.2169/naika.86.947.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Atif, Qurrat Al Ain, and Adel Hamed. "Isolated internal jugular and subclavian vein thrombosis: a rare complication of pancreatitis. A case report." Journal of the Pakistan Medical Association 72, no. 4 (April 5, 2022): 752–54. http://dx.doi.org/10.47391/jpma.1493.

Full text

Abstract:

Splanchnic vein thromboses are well recognized vascular complications of acute as well as chronic pancreatitis. Extra splanchnic thromboses have rarely been reported. One such case of a 41-year-old Pakistani male patient who developed acute alcoholic pancreatitis is presented. On further workup he was found to have bilateral internal jugular and subclavian vein thrombosis with patent splanchnic veins. Pancreatitis generally creates a procoagulant state in the body. Moreover, the inflammatory process itself along with compression from peri-pancreatic fluid collections cause injury to the nearby vessels resulting in vascular complications. Whether venous or arterial, vascular complications of acute or chronic pancreatitis have fatal consequences. Extra splanchnic venous thromboses do occur and should be sought for, if symptoms indicate. Internal jugular and subclavian vein thrombosis can lead to pulmonary embolism and mortality. Hence appropriate timely diagnosis and effective treatment should be commenced to avoid any untoward consequences. Keywords: pancreatitis, splanchnic vein thrombosis, extra splanchnic vein thrombosis, pancreatic pseudocyst. Continue...

APA, Harvard, Vancouver, ISO, and other styles

42

Zhang, Steven Liben, and Hui Wen Ng. "Primary thrombolysis for free flap surgery in head and neck reconstruction: a case report and review." Archives of Plastic Surgery 48, no. 5 (September 15, 2021): 511–17. http://dx.doi.org/10.5999/aps.2021.00171.

Full text

Abstract:

The use of free flaps is an essential and reliable method of reconstruction in complex head and neck defects. Flap failure remains the most feared complication, the most common cause being pedicle thrombosis. Among other measures, thrombolysis is useful when manual thrombectomy has failed to restore flap perfusion, in the setting of late or established thrombosis, or in arterial thrombosis with distal clot propagation. We report a case of pedicle arterial thrombosis with distal clot propagation which occurred during reconstruction of a maxillectomy defect, and was successfully treated with thrombolysis using recombinant tissue plasminogen activator. We also review the literature regarding the use of thrombolysis in free flap surgery, and propose an algorithm for the salvage of free flaps in head and neck reconstruction.

APA, Harvard, Vancouver, ISO, and other styles

43

Mouton, Zehnder, Wagner, and Mouton. "Follow-up after deep venous thrombosis in azygos continuation." Vasa 34, no. 4 (November 1, 2005): 266–68. http://dx.doi.org/10.1024/0301-1526.34.4.266.

Full text

Abstract:

Background: To determine the sequelae of patients after deep venous thrombosis in patients with azygos continuation defined as agenesis of the inferior vena cava with collateral flow. Patients and methods: Five patients post deep venous thrombosis in the context of azygos continuation were followed up clinically and with colour duplex ultrasonography. Results: All five patients had to our knowledge after the initial deep venous thrombosis no further thromboembolic events. Three patients after isolated iliac thromboses are symptom free or nearly symptom free, two after more extended thromboses still suffer from venous claudication. Four patients are without anticoagulation, one patient is permanently orally anticoagulated. Conclusions: Azygos continuation may not influence the risk of recurrent venous thrombo-embolism nor the outcome of a deep venous thrombosis. Careful deep venous thrombosis prophylaxis in patients with azygos continuation may be sufficient when a risk factor is present but conclusions lack due to the small numbers of patients of enough supportive data.

APA, Harvard, Vancouver, ISO, and other styles

44

Tuite, Paul, Ferhaan Ahmad, Ian Grant, John D. Stewart, Stirling Carpenter, and Romeo Ethier. "Cerebral Vein Thrombosis due to Hereditary Antithrombin III Deficiency." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 20, no. 2 (May 1993): 158–61. http://dx.doi.org/10.1017/s0317167100047752.

Full text

Abstract:

ABSTRACT:Cerebral vein thrombosis, also called superior sagittal sinus thrombosis, is a well recognized clinical and radiologic entity associated with a variety of medical disorders. We report a patient with fatal cerebral vein thrombosis following myelography, in whom the cause was familial antithrombin III (AT3) deficiency. Unsuspected AT3 deficiency should be considered in cases of unexplained cerebral venous thromboses.

APA, Harvard, Vancouver, ISO, and other styles

45

GHANIMA, W., I. W. KLEVEN, T. ENDEN, A. ROSALES, H. S. WIK, L. PEDERSTAD, P. A. HOLME, and P. M. SANDSET. "Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis." Journal of Thrombosis and Haemostasis 9, no. 6 (June 2011): 1261–63. http://dx.doi.org/10.1111/j.1538-7836.2011.04298.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Mattar, Mervat, Sahar Nassef, Noha M. El Husseiny, Mohamed Abdel Kader Morad, Marwa Salah, Mohamed Roshdy El Masry, and Ahmed Abdul Gawad. "Incidence of Silent Thrombosis in Myeloproliferative Neoplasm Patients below 60 Years : Single Center Egyptian Study." Blood 132, Supplement 1 (November 29, 2018): 5476. http://dx.doi.org/10.1182/blood-2018-99-116025.

Full text

Abstract:

Abstract Background : Identification of JAK-2 mutation even in absence of myeloproliferative disorders was found to be related to venous thromboembolism occurrence. The aim of this work is to screen myeloproliferative neoplasm ( MPN) patients for venous thrombosis and study its correlation with both JAK 2 allele burden and with symptoms the patients presented with. Methods: We enrolled 73 cases with JAK2 positive MPN in the period between August 2015 till Feb 2017. All patients were screened for thrombosis in venous system in neck, upper and lower limbs, superior and inferior Venae Cavae and portal and mesenteric venous systems system using color Doppler Ultrasound. Results: 53 patients (72.6%) were below 60 years. Forty even (64.4%) were females and 26(35%) were males. Twenty two (30%) of cases were Essential Thrombocytosis (ET), 35(248%) were Polycythemia Vera (PV) and 16 (22%) were Myelofibrosis (MF). Twenty seven venous thrombotic attacks were reported in twenty two patients (30.1%). Seventeen patients (23%) had mesenteric and portal vein thrombosis,six patients had iliofemoral (8%) and 4 (5%) had combined lower limb and portal thrombosis. Eight patients (10.8%) had active thrombosis at screening. Only three (4%) patient were symptomatising with pain during screening. Sixteen patients with thrombosis were below 60 (30% of those below 60 years) and 6 were above sixty years (also 30% of those above sixty years). Correlation analysis between JAK2 allele burden and thrombosis was not statistically significant (r=0.3 ,p value=0.5). However, JAK 2 allele burden was statistically higher in those above sixty years in both thrombosed and non-thrombosed cases in comparison to those below sixty years (p= 0.03, 0.017 respectively). The incidence of pruritis (p =0.02) and of abdominal pain (p=0.039) was significantly different between thrombosed and non-thrombosed cases. Comparison of 8 cases with active thrombosis to old thrombosis revealed no statistical difference in the MPN10 score (p>0.05). Conclusion: We recommend routine screen for venous thrombosis in any case of MPNs once diagnosed and screening for MPNs in any case with venous thrombosis . Further research in MPN group age below 60 years of age is highly recommended. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

47

Kitrou, Panagiotis, Marios Papasotiriou, Konstantinos Katsanos, Dimitrios Karnabatidis, Dimitrios S. Goumenos, and Evangelos Papachristou. "Recent developments in endovascular interventions to sustain vascular access patency in haemodialysis patients." Nephrology Dialysis Transplantation 34, no. 12 (December 5, 2018): 1994–2001. http://dx.doi.org/10.1093/ndt/gfy354.

Full text

Abstract:

Abstract There is amassed evidence regarding the use of endovascular procedures for the treatment of vascular access stenosis and thrombosis. A review was conducted based on available randomized trials, cohort studies and retrospective analyses published after 2000 on endovascular treatment of dysfunctional and thrombosed vascular access, with an aim to illustrate the available device and procedural options. The use of paclitaxel-coated balloons, cutting balloons and covered stents is described in the field of vascular access stenosis. The broad spectrum of available devices and endovascular declotting procedures ranging from thrombolysis to thrombectomy is also discussed. Overall, in this review we demonstrate the increasing role of endovascular procedures in vascular access treatment and the improved patency outcomes provided by the implementation of novel endovascular devices. Moreover, the improvement of post-intervention primary patency rates after endovascular declotting procedures and the shift to more thrombectomy-dependent procedures over time is also highlighted. In conclusion, endovascular treatment of dialysis access stenosis and thrombosis has an established role, owing to the implementation of sophisticated devices, allowing, when needed, the simultaneous treatment of thrombosis and the underlying stenosis.

APA, Harvard, Vancouver, ISO, and other styles

48

Wever, M. L. G., K. D. Liem, W. B. Geven, and R. B. Tanke. "Urokinase Therapy in Neonates with Catheter Related Central Venous Thrombosis." Thrombosis and Haemostasis 73, no. 02 (1995): 180–85. http://dx.doi.org/10.1055/s-0038-1653748.

Full text

Abstract:

SummaryThe results of fibrinolytic therapy with urokinase were evaluated in 26 neonates with catheter related central venous thrombosis. Complete thrombolysis could be achieved in 13 patients (50%), partial thrombolysis in 3 patients (12%). No effect was seen in 10 patients (38%). Therapy success was influenced by age, size and location of the thrombus. Coincidence of infection occurred in 16 patients (62%). Mild hemorrhagic complications were seen in 2 patients (8%), no other significant side effects were observed. Nine patients with residual thrombosis were treated with oral anticoagulants following urokinase resulting in resolution of the thrombus in 6 patients within 3 months (67%). The incidence of asymptomatic recurrent thrombosis was high (28%). Urokinase might be an effective and safe treatment for central venous thrombosis in neonates. Prophylactic antibiotic therapy during the infusion of urokinase and long-term treatment with oral anticoagulants after thrombosis are advisable. Early detection of thrombosis might enhance the success rate of fibrinolytic therapy. Therefore, we strongly recommend routine echocardiographic screening of central venous catheters.

APA, Harvard, Vancouver, ISO, and other styles

49

Reshetnyak, Tatiana M., Fariza A. Cheldieva, Svetlana I. Glukhova, Kamila S. Nurbaeva, Nataliya V. Seredavkina, Mariya V. Cherkasova, Alexander M. Lila, and Evgeny L. Nasonov. "Thrombotic antiphospholipid syndrome: Recurrent thromboses." Rheumatology Science and Practice 62, no. 4 (September 2, 2024): 408–17. http://dx.doi.org/10.47360/1995-4484-2024-408-417.

Full text

Abstract:

Thrombotic antiphospholipid syndrome (APS) is a condition affecting young people in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).The aim of this study was the evaluation of the incidence of recurrent thrombosis and its risk factors in antiphospholipid syndrome.Material and methods. The retrospective study included 98 patients with aPL who were followed up at the institute from 2014 to 2023, of whom 66 (67%) were women and 32 (33%) were men. Of the 98 patients with aPL, 48 (49%) had a diagnosis of systemic lupus erythematosus (SLE). Antiphospholipid antibodies (aPL), including antibodies to cardiolipin (IgG/IgM aCL), antibodies to ß2-glycoprotein 1 (IgG/IgM aß2GP1), antibodies to ß2-glycoprotein IgG against domain 1 (IgG aß2GP1-D1), antibodies to phosphatidylserine/prothrombin complex (IgG/ IgM aPS/PT) and other thrombotic risk factors. aPL was assessed by enzyme-linked immunosorbent assay (ELISA) and chemoluminescence assay (CHLA).Results. Thrombosis recurrence was reported in 62 (63%) of 98 patients, and 36 (35%) did not. The main cause of recurrent thrombosis was treatment with direct oral anticoagulants (DOACs). 24 (38.7%) of 62 patients with recurrent thrombosis were treated with DOACs, the duration of which ranged from 6 to 24 months. The next most common cause of recurrent thrombosis was the lack of continuous anticoagulant therapy in 20 (32.5%) of the patients. In 17 (27.4%) of the patients, the recurrence occurred while they were still taking warfarin. In 10 (41.7%) of the 24 patients, the recurrent thrombosis was arterial in origin. This was associated with recurrent cerebral circulation problems. The level of positivity did not matter, but all had triple IgG aPL positivity. 5 had lupus anticoagulant (LA) at the onset of the disease before anticoagulant use. IgG aPS/PT was most important in association with recurring thrombosis in the ELISA: 45 (72.6%) of 62 patients with recurring thrombosis were positive for IgG aPS/PT, compared with 19 (52.8%) of 36 patients without recurring thrombosis. The detection of all aPL was more frequent in CHMA than in ELISA. However, the definition of aPL in ELISA is recommended according to the latest classification criteria. Triple IgG positivity for aCL of IgG aß2GP1, IgG aß2GP1-D1 and CHMA remained a risk factor for recurrent thrombosis and increased the risk of recurrence more than threefold. Obesity was a risk factor for recurrent thrombosis, with a 5-fold increased risk of recurrent thrombosis in obese compared to non-obese patients (p=0.01).Conclusions. Recurrent thrombosis in APS is largely associated with IgG aCL, IgG aß2GP1, IgG aß2GP1-D1, IgG aPS/PT. Triple IgG aPL positivity in any combination significantly increased recurrent thrombosis risk.The presence of any type of aPL IgG in both ELISA and CHLA influenced the recurrence rate of thrombosis in APS.Obesity was a significant risk factor for recurrent thrombosis.

APA, Harvard, Vancouver, ISO, and other styles

50

SUEHIRO, AKIRA. "Thrombosis. Thrombosis : Advances on diagnosis and treatment. Disease state and diagnosis of thrombotic diseases. Multiple small vein thrombosis. Thrombotic thrombopenic purpura (TTP)." Nihon Naika Gakkai Zasshi 86, no. 6 (1997): 923–28. http://dx.doi.org/10.2169/naika.86.923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Thrombosis'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles